{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Number of participants who had a documented complete response (CR) or partial response (PR) at any time during study treatment. Disease response/progression by PET-CT or CT was evaluated using 2014 Lugano Classification.","groups":[{"description":"Patients receive pralatrexate 20mg/m2 IV over 3-5 minutes on days 1 and 8 and pembrolizumab 200mg IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Phase I - Dose Level 1: Pembrolizumab 200mg + Pralatrexate 20mg/m2"},{"description":"Patients receive pralatrexate 30mg/m2 IV over 3-5 minutes on days 1 and 8 and pembrolizumab 200mg IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Phase I - Dose Level 2: Pembrolizumab 200mg + Pralatrexate 30mg/m2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 43 months after the initial study treatment.","title":"Number of Participants Who Had Overall Response","type":"PRIMARY","unitOfMeasure":"Participants"}